NO20091830L - Spiro-piperidinderivater som VIa reseptorantagonister - Google Patents

Spiro-piperidinderivater som VIa reseptorantagonister

Info

Publication number
NO20091830L
NO20091830L NO20091830A NO20091830A NO20091830L NO 20091830 L NO20091830 L NO 20091830L NO 20091830 A NO20091830 A NO 20091830A NO 20091830 A NO20091830 A NO 20091830A NO 20091830 L NO20091830 L NO 20091830L
Authority
NO
Norway
Prior art keywords
spiro
receptor antagonists
piperidine derivatives
via receptor
present
Prior art date
Application number
NO20091830A
Other languages
English (en)
Norwegian (no)
Inventor
Patrick Schnider
Hasane Ratni
Caterina Bissantz
Christophe Grundschober
Mark Rogers-Evans
Rafaello Masciadri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20091830L publication Critical patent/NO20091830L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20091830A 2006-12-07 2009-05-11 Spiro-piperidinderivater som VIa reseptorantagonister NO20091830L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06125634 2006-12-07
PCT/EP2007/062985 WO2008068185A1 (fr) 2006-12-07 2007-11-29 Dérivés de spiro-pipéridine

Publications (1)

Publication Number Publication Date
NO20091830L true NO20091830L (no) 2009-07-06

Family

ID=39295880

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091830A NO20091830L (no) 2006-12-07 2009-05-11 Spiro-piperidinderivater som VIa reseptorantagonister

Country Status (21)

Country Link
US (3) US20080139554A1 (fr)
EP (1) EP2102207B1 (fr)
JP (1) JP2010511661A (fr)
KR (1) KR101050568B1 (fr)
CN (1) CN101547923A (fr)
AR (1) AR064135A1 (fr)
AT (1) ATE469900T1 (fr)
AU (1) AU2007328995B2 (fr)
BR (1) BRPI0720004A2 (fr)
CA (1) CA2670674A1 (fr)
CL (1) CL2007003482A1 (fr)
DE (1) DE602007006990D1 (fr)
ES (1) ES2344131T3 (fr)
IL (1) IL198544A (fr)
MX (1) MX2009005504A (fr)
NO (1) NO20091830L (fr)
PE (1) PE20081252A1 (fr)
RU (1) RU2009119394A (fr)
TW (1) TW200838518A (fr)
WO (1) WO2008068185A1 (fr)
ZA (1) ZA200903496B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0721138A2 (pt) 2006-12-22 2014-04-01 Hoffmann La Roche Derivados de espiro-piperidina
CN102015711B (zh) 2008-04-29 2013-05-01 诺瓦提斯公司 用于治疗寄生虫病的螺-吲哚衍生物
JP6629855B2 (ja) * 2014-11-14 2020-01-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ スピロチアゾロン
WO2017137334A1 (fr) * 2016-02-08 2017-08-17 F. Hoffmann-La Roche Ag Spiroindolinones utilisés en tant qu'inhibiteurs de ddr1
EP3679043B9 (fr) 2017-09-05 2023-09-27 Neumora Therapeutics, Inc. Antagonistes du récepteur de la vasopressine, produits et procédés associés

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3370091A (en) * 1964-06-15 1968-02-20 Hoffmann La Roche 2 aminobenzhydrylhalides
US3531467A (en) * 1966-12-23 1970-09-29 Hoffmann La Roche Process for the preparation of 2,3,4,5-tetrahydro - 5 - aryl - 1h - 1,4 - benzodiazepine derivatives
US4209625A (en) * 1977-04-21 1980-06-24 American Hoechst Corporation Spiro[indoline-3,4'-piperidine]s
DE3818830A1 (de) * 1988-06-03 1989-12-14 Boehringer Mannheim Gmbh Bicyclische carboxamide, verfahren zu ihrer herstellung, deren vorstufen, und diese verbindungen enthaltende arzneimittel
EP0450761A1 (fr) * 1990-03-02 1991-10-09 Merck & Co. Inc. Antagonistes d'oxytocine spirocycliques
DK78692D0 (da) 1992-06-12 1992-06-12 Lundbeck & Co As H Dimere piperidin- og piperazinderivater
WO1994007496A1 (fr) 1992-10-07 1994-04-14 Merck & Co., Inc. Antagonistes recepteurs d'oxytocine tocolytique
US5670509A (en) * 1993-09-27 1997-09-23 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
IT1271026B (it) 1994-10-21 1997-05-26 Isagro Ricerca Srl Derivati dell'acido b-amminopropionico ad attivita' fungicida
US5576321A (en) 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
CN1208412A (zh) 1995-12-14 1999-02-17 麦克公司 促性腺激素释放激素拮抗剂
GB9601724D0 (en) * 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
US6166209A (en) 1997-12-11 2000-12-26 Hoffmann-La Roche Inc. Piperidine derivatives
CO5150201A1 (es) 1998-09-07 2002-04-29 Hoffmann La Roche Derivados de piperidina
TWI279402B (en) * 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same
GB0003397D0 (en) 2000-02-14 2000-04-05 Merck Sharp & Dohme Therapeutic agents
EP1283838B1 (fr) 2000-05-12 2003-12-03 Solvay Pharmaceuticals B.V. Composes de piperazine et piperidine
AU2001292579A1 (en) 2000-09-29 2002-04-15 Eli Lilly And Company Methods and compounds for treating proliferative diseases
US6596718B1 (en) 2001-11-27 2003-07-22 Hoffmann-La Roche Inc. 7-Morpholin-4yl-benzothiazole amide derivatives
FR2833948B1 (fr) 2001-12-21 2004-02-06 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et leur utilisation en tant que medicament
US20040152741A1 (en) 2002-09-09 2004-08-05 Nps Allelix Corporation Arylglycine derivatives and their use as glycine transport inhibitors
WO2004026855A1 (fr) 2002-09-20 2004-04-01 H. Lundbeck A/S Procede de preparation de derives de dihydroisobenzofuranne
PL377215A1 (pl) 2002-10-17 2006-01-23 Amgen Inc. Pochodne benzimidazolu oraz ich zastosowanie w charakterze ligandów receptora waniloidowego
AU2003215549A1 (en) 2003-02-03 2004-08-30 Janssen Pharmaceutica N.V. Mercaptoimidazoles as ccr2 receptor antagonists
US7244852B2 (en) * 2003-02-27 2007-07-17 Abbott Laboratories Process for preparing 2-methylpyrrolidine and specific enantiomers thereof
ATE482747T1 (de) * 2003-04-11 2010-10-15 High Point Pharmaceuticals Llc Neue amide derivate und deren pharmazeutische verwendungen
US7504506B2 (en) 2003-11-04 2009-03-17 Elixir Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
EA010132B1 (ru) * 2003-12-22 2008-06-30 Пфайзер Инк. Производные триазола в качестве антагонистов вазопрессина
JP2007516298A (ja) 2003-12-23 2007-06-21 アリーナ ファーマシューティカルズ， インコーポレイテッド 新規なスピロインドリンまたはスピロイソキノリン化合物、それらの使用方法および組成物
GB0400700D0 (en) * 2004-01-13 2004-02-18 Pfizer Ltd Compounds useful in therapy
AU2005268893B2 (en) 2004-08-05 2011-10-13 F. Hoffmann-La Roche Ag Indole, indazole or indoline derivatives
EP1802623A1 (fr) 2004-10-12 2007-07-04 Novo Nordisk A/S Composes spiro actifs du type a- hydroxysteroide deshydrogenase de type 1
US8599298B2 (en) * 2004-10-13 2013-12-03 Sony Corporation Reproduction apparatus, imaging apparatus, screen display method, and user interface
CA2608718A1 (fr) 2005-05-18 2006-11-23 Pfizer Limited Derives de 1, 2, 4-triazole en tant qu'antagonistes de la vasopressine
US8190027B2 (en) * 2006-07-12 2012-05-29 Tellabs Operations, Inc. Multifunctional and reconfigurable optical node and optical network
CA2615726C (fr) 2005-07-14 2014-05-27 Caterina Bissantz Derives d'indol-3-yl-carbonyl-spiro-piperidine en tant qu'antagonistes du recepteur v1a
WO2007028638A1 (fr) 2005-09-09 2007-03-15 Euro-Celtique S.A. Composes fondus et spirocycle ainsi que l'utilisation de ceux-ci
BRPI0721138A2 (pt) * 2006-12-22 2014-04-01 Hoffmann La Roche Derivados de espiro-piperidina
ATE486877T1 (de) * 2006-12-29 2010-11-15 Hoffmann La Roche Azaspiroderivate
CN101583615B (zh) * 2007-01-12 2012-07-04 弗·哈夫曼-拉罗切有限公司 螺哌啶甘氨酰胺衍生物

Also Published As

Publication number Publication date
US20080139554A1 (en) 2008-06-12
ES2344131T3 (es) 2010-08-18
AU2007328995A1 (en) 2008-06-12
CN101547923A (zh) 2009-09-30
JP2010511661A (ja) 2010-04-15
KR20090079255A (ko) 2009-07-21
ZA200903496B (en) 2010-03-31
RU2009119394A (ru) 2011-01-20
IL198544A0 (en) 2010-02-17
EP2102207A1 (fr) 2009-09-23
CA2670674A1 (fr) 2008-06-12
PE20081252A1 (es) 2008-09-04
US20080139553A1 (en) 2008-06-12
AR064135A1 (es) 2009-03-18
AU2007328995B2 (en) 2012-04-26
IL198544A (en) 2012-06-28
US8202993B2 (en) 2012-06-19
ATE469900T1 (de) 2010-06-15
BRPI0720004A2 (pt) 2013-12-17
EP2102207B1 (fr) 2010-06-02
CL2007003482A1 (es) 2008-07-04
MX2009005504A (es) 2009-06-03
WO2008068185A1 (fr) 2008-06-12
KR101050568B1 (ko) 2011-07-19
DE602007006990D1 (de) 2010-07-15
US20080146568A1 (en) 2008-06-19
TW200838518A (en) 2008-10-01

Similar Documents

Publication Publication Date Title
NO20092342L (no) Azaspiroderivativater
NO20091766L (no) Spiro-piperidinderivater
NO20074592L (no) Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
NO20092149L (no) Spiro-piperidinderivater
NO20073719L (no) Kjemiske forbindelser
NO20070199L (no) Substituerte kinazoloner som anti-kreftmidler
NO20082709L (no) Kjemiske forbindelser
NO20073876L (no) Pyrazolopyrimidinderivater som mGluR2-antagonister
NO20074258L (no) Pyridin-2-karboksamidderivater som MGLUR5 antagonister
NO20072784L (no) Pyridenkarboksamidderivater for anvendelse som anticancer midler
NO20070489L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
NO20085100L (no) Nye forbindelser
NO20060324L (no) [1,8]Naftyridin-2-oner og relaterte forbindelser for behandling av Schizofreni
NO20090328L (no) Nye forbindelser 385
NO20091683L (no) Kjemiske forbindelser
NO20076197L (no) Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander
NO20076195L (no) Nye 2-azetidinonderivater for behandling av hyperlipidemiske sykdommer
NO20071246L (no) Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer.
NO20063469L (no) Polyeheterosykliske forbindelser og deres anvendelse som metabotrofe glutamat reseptorantagonister
NO20055688L (no) Organiske forbindelser
NO20084363L (no) 2-Substituerte 4-benzylftalazinonderivater som histamin H1- og H3-antagonister
NO20084202L (no) 4-anilinoquinolin-3-carboksamider som CSF-1R kinase inhibitorer
NO20083905L (no) Nye pyron-indol derivater og fremgangsmate for deres fremstilling
NO20076060L (no) Piperidin-4-yl-amidderivater og deres anvendelse som SST-reseptor subtype 5-antagonister
NO20092689L (no) Quinuclidinolderivater som muskarin reseptorantagonister

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application